Navigation Links
New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population
Date:9/1/2011

WASHINGTON, Sept. 1, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive.  The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.  

Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation. According to the FDA, the mutation is only present in 1-7% of people with NSCLC, primarily those diagnosed with adenocarcinoma.

"This is exciting news," said LCA President & CEO, Laurie Fenton Ambrose.  "Personalized medicine is where we are headed for lung cancer treatments.  This is one of the first steps towards identifying medications that help select populations of people.  We must continue to identify other mutations and find drugs that treat them to finally see cures for lung cancer." 

"I was enrolled in the phase I trial for this drug," said Linnea Duff, NH resident and longtime lung cancer survivor.  "At the time I began the trial, I was hoping to have my life extended for a few months. Instead, I got three more years to spend with my family and friends. In addition, because this was a targeted therapy, the side effects were minimal and my quality of life during this time has been remarkable."

Xalkori has shown a life changing response to lung cancer in those patients who are ALK positive.  Lung Cancer Alliance encourages lung cancer patients to discuss genetic testing options with their health care team.  

It is important to note that many genetic mutations have been identified but not all have drugs to target the mutations at this time. With continued focus from researchers and increased participation in clinical trials, more and more of these personalized therapies will become available.  

For more information about clinical trials, please call the Lung Cancer Clinical Trial Matching Service, 800-698-0931.

Lung Cancer Alliance is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.  Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance  

Media Contact:
Kay Cofrancesco
kay@lungcanceralliance.org
202-463-2080


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May Be Ineffective and Unsafe
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
4. Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. TandemHeart Approved for Expanded Reimbursement
6. Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List
7. Laureates Electronic Submission Gateway Approved
8. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
9. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
10. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
11. FDA Expands Approved Use For Carotid Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
(Date:2/24/2017)... , Feb. 24, 2017 Medical information ... to increase their self-service capabilities to manage inquiries ... (HCPs). New research from consulting leader ... have developed self-service website portals where HCPs can ... just one of many findings to emerge from ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care ... Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade to its ... look for home care close to home, and by having city-specific pages, NuevaCare is ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and ... may explain why susceptibility to one of the disorders could place individuals at lower ... the journal npj Schizophrenia. , “There is a wealth of genomic data on ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
Breaking Medicine News(10 mins):